RxDoctor Payments Data

Whitney Whitfield, MD

Ophthalmology · Tallahassee, FLNPI 1285168773

Payments from drug & device makers

$1,047in general payments, 2019–2025

Across 34 payments — averaging $30.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$246
  • Bausch & Lomb Americas Inc.$205
  • Alcon$171
  • Aerie Pharmaceuticals, Inc.$120
  • Glaukos Corporation$69
  • AbbVie$66
  • plus $169 from 5 others

What the payments were for

  • Food & beverage$1,047100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,047 in reported general payments places this provider in the 35th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$243,926
Medicare patients
980
Services billed
2,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TepezzaTeprotumumab-Trbw12$669,940
RestasisCyclosporine75$59,912
RocklatanNetarsudil Mesylat/Latanoprost17$7,193
Latanoprost564$6,305
LumiganBimatoprost12$5,901
Alphagan PBrimonidine Tartrate19$5,707
Brimonidine Tartrate280$5,230
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat240$4,027
Prednisolone Acetate97$3,900
Travoprost13$3,326
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$2,114
Acetazolamide18$1,283
ErythromycinErythromycin Base110$1,212
Tobramycin-DexamethasoneTobramycin/Dexamethasone23$1,013
Timolol Maleate118$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenTepezza$246$669,94012 claims
AbbVieRestasis, Lumigan, Alphagan P$66$71,521106 claims
Aerie Pharmaceuticals, Inc.Rocklatan$120$7,19317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →